Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Patent
1997-09-09
1998-11-24
Prouty, Rebecca E.
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
435212, 4351723, 4352523, 43525233, 4353201, 536 232, 536 235, C07H 2104, C12N 964
Patent
active
058405640
ABSTRACT:
Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.
REFERENCES:
patent: 4752603 (1988-06-01), Collen et al.
patent: 4753879 (1988-06-01), Rosa
patent: 4766075 (1988-08-01), Goeddel et al.
patent: 4772585 (1988-09-01), Sarnoff
patent: 4837022 (1989-06-01), Kakimoto
patent: 4839169 (1989-06-01), Whittle
patent: 4935237 (1990-06-01), Higgins et al.
patent: 4960702 (1990-10-01), Rice et al.
patent: 4968617 (1990-11-01), Johnston et al.
patent: 4980165 (1990-12-01), Isaacs et al.
patent: 5041376 (1991-08-01), Gething et al.
patent: 5108901 (1992-04-01), Anderson et al.
patent: 5112609 (1992-05-01), Johnston et al.
patent: 5232847 (1993-08-01), Edwards et al.
patent: 5242688 (1993-09-01), Burck et al.
patent: 5246850 (1993-09-01), Bennett et al.
patent: 5258180 (1993-11-01), Gill et al.
patent: 5262170 (1993-11-01), Anderson et al.
patent: 5270198 (1993-12-01), Anderson et al.
patent: 5304482 (1994-04-01), Sambrook et al.
patent: 5342616 (1994-08-01), Cohen
patent: 5344773 (1994-09-01), Wei et al.
patent: 5346824 (1994-09-01), Anderson et al.
patent: 5366730 (1994-11-01), Kohnert et al.
patent: 5385732 (1995-01-01), Anderson et al.
patent: 5405771 (1995-04-01), Anderson et al.
patent: 5409699 (1995-04-01), Kohnert et al.
patent: 5411871 (1995-05-01), Anderson et al.
patent: 5486602 (1996-01-01), Sambrook et al.
patent: 5520911 (1996-05-01), Anderson et al.
patent: 5520913 (1996-05-01), Anderson et al.
Agnelli et al., "Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits" Blood 66(2):399-401 (1985).
Berman et al., "Engineering Glycoproteins for Use as Pharmaceuticals" Trends in Biotechnology 3(2):51-53 (Feb. 1985).
Browne et al., "A Tissue-Type Plasminogen Activator Mutant with Prolonged Clearance In Vivo" Journal of Biological Chemistry 263(4):1599-1602 (1988).
Cambier et al., "Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis" J. Cardiovasc. Pharmacol. 11:468 (1988).
Eisenberg et al., "Sustained Fibrinolysis After Administration of t-PA despite its short half-life in the circulation" Thrombosis and Haemostasis 57(1):35-40 (1987).
Eisert et al., "Bolus treatment regimen of t-PA expedites rate of lysis in vivo without increasing risk of bleeding" Haemostasis (Abstract, 5th Congress of the Society on Thromb. and Haemost. (Feb. 1988) Frankfurt) pp. 85 (114) (1988).
Eisert et al., "Repeated bolus administration of rTPA at 30 minute intervals lyses clots as efficiently as continuous 2 hour infusion" Blood (Supplement) (Abstract (28th Annual Mtg of the Am. Society of Hematol. (Dec. 1986)) 68(5):1208 (1986).
Gardell et al., "Isolation, Characterization, and cDNA Cloning of a Vampire Bat Salivary Plasminogen Activator" Journal of Biological Chemistry 264(30):17947-17952 (Oct. 25, 1989).
Gold and Leinbach, "Prevention of acute reocclusion after thrombolysis with intravenous recombinant tissue plasminogen activator" Tissue Plasminogen Activator in Thrombolytic Therapy, Sobel et al., New York:Dekker vol. Chapter 7:115-130 (1987).
Gold et al., "Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation" Circulation 77(3):670-677 (1988).
Gunzler, W. et al., "The Primary Structure of High Molecular Mass Urokinas from Human Urine The Complete Amino Acid Sequence of the A Chain," Hoppe-Seyler's Z. Physiol. Chem. Bd. 363:S. 1155-1165 (1982).
Harris, "Second-Generation Plasminogen Activators" Protein Engineering 1(6):449-458 (1987).
Holmes, W., et al., "Cloning and Expression of the Gene for Pro-Urokinase in Escherichia coli," Bio/Technology 3:923-929 (1985).
Huber and Bode, "Structural Basis of the Activation and Action of Trypsin" Accounts of Chemical Research 11:114-122 (1978).
Kasai, S. et al., "Proteolytic Cleavage of Single-chain Pro-urokinase Induces Conformational Change which Follows Activation of the Zymogen and Reduction of Its High Affinity for Fibrin," Journal of Biological Chemistry 260(22):12377-12381 (1985).
Kasai, S. et al., "Thrombolytic Properties of an Inactive Proenzyme Form of Human Urokinase Secreted from Human Kidney Cells," Cell Structure and Function 10:151-159 (1985).
Kassell and Kay, "Zymogens of Proteolytic Enzymes" Science 180:1022-1027 (1973).
Kaufman et al., "Expression and Amplification of DNA Introduced into Mammalian Cells" Gene Amplification, Cold Spring Harbor Laboratory pp. 245-250 (1982).
Ladenheim, R.G. et al., "N-Linked Glycosylation Affects the Processing of Mouse Submaxillary Gland Prorenin in Transfected AtT20 Cells" European Journal of Biochemistry 198(2):535-540 (1991).
Machamer and Rose, "Influence of New Glycosylation Sites on Expression of the Vesicular Stomatitis Virus G Protein at the Plasma Membrane" Journal of Biological Chemistry 263(12):5948-5954 (1988).
Machamer and Rose, "Vesicular Stomatitis Virus G Proteins with Altered Glycosylation Sites Display Temperature-Sensitive Intracellular Transport and Are Subject to Aberrant Intermolecular Disulfide Bonding" Journal of Biological Chemistry 263(12):5955-5960 (1988).
Madison et al., "Amio acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1" Proc. Natl. Acad. Sci. USA 87:3530-33 (1990).
Madison et al., "Serpin-Resistant Mutants of Human Tissue-Type Plasminogen Activator" Nature 339:721-724 (1989).
Montz et al., "The ability of recombinant tissue plasminogen activator to inhibit post-radical pelvic surgery adhesions in the dog model" Am. J. Obstet. Gynecol. 165(5 Pt. 1):1539-1542 (1991).
Ny et al., "Cloning and Characterization of a cDNA for Rat Tissue-Type Plasminogen Activator" DNA 7(10):671-677 (1988).
Pados and Devroey, "Adhesions" Curr. Opin. Obstet. Gynecol. 4(3):412-418 (1992).
Pannekoek et al., "Mutants of human tissue-type plasminogen activator (t-PA): structural aspects and functional properties" Fibrinolysis 2:123-132 (1988).
Pennica et al., "Cloning and Expression of Human Tissue-type Plasminogen Activator cDNA in E. coli," Nature 301:214-221 (1983).
Petersen et al., "The effect of polymerised fibrin on the catalytic activities of one-chain tissue-type plasminogen activator as revealed by an analogue resistant to plasmin cleavage" Biochemica Et Biophysica Acta 952:245-254 (1988).
Pharmacia Fine Chemicals Catalogue 84(1 and 6) (1984).
Rickles et al., "Molecular Cloning of Complementary DNA to Mouse Tissue Plasminogen Activator mRNA and Its Expression During F9 Teratocarcinoma Cell Differentiation" Journal of Biological Chemistry 263(3):1563-1569 (1988).
Rijken and Collen, "Purification and Characterization of the Plasminogen Activator Secreted by Human Melanoma Cells in Culture," Journal of Biological Chemistry 256(13):7035-7041 (1981).
Rijken et al., "Fibrinolytic Properties of One-chain and Two-chain Human Extrinsic (Tissue-type) Plasminogen Activator" Journal of Biological Chemistry 257:2920-2925 (1982).
Ringe, D., "The Sheep in Wolf's Clothing" Nature 339:658-659 (1989).
Ross et al., "Plasminogen Activators" Annual Reports in Medicinal Chemistry, Richard C. Allen, ed., Academic Press, Inc., Chapter 12, vol. 23:111-120 (1988).
S
Anderson Stephen
Bennett William F.
Bottstein David
Higgins Deborah L.
Paoni Nicholas F.
Dreger Ginger R.
Genentech Inc.
Nashed Nashaat T.
Prouty Rebecca E.
LandOfFree
Tussue plasminogen activator having zymogenic or fibrin specific does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tussue plasminogen activator having zymogenic or fibrin specific, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tussue plasminogen activator having zymogenic or fibrin specific will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1700944